Instruction 1(b)

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287										
Estimated average burd	Estimated average burden									
hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Smith Hunter C							2. Issuer Name and Ticker or Trading Symbol <u>RHYTHM PHARMACEUTICALS, INC.</u> [ <u>RYTM</u> ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
															ctor er (give title		10% Ov Other (s	· ·		
(Last) (First) (Middle)							3. Date of Earliest Transaction (Month/Day/Year)							X below) below) Chief Financial Officer						
222 BERKELEY STREET, 12TH FLOOR						02/11/2021														
(Street)						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
BOSTON MA 02116												X Form filed by One Reporting Person								
													Form filed by More than One Reporting Person							
(City) (State) (Zip)																				
		Tab	ole I - Non	-Deriv	ative	e Se	curities	s Ac	quired	l, Dis	sposed o	of, or Be	neficia	lly Own	ed					
1. Title of Security (Instr. 3) 2. Transau Date (Month/Date)						Execution Date			Code (Instr. 5)		ed (A) or str. 3, 4 ar	d Secu Bene Owne	icially d Following	Form (D) o	rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership				
								Code	e v	Amount	(A) or (D) Pric			action(s) 3 and 4)			(Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivati Security	re derivativ	re es ally g	Ownershij Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership t (Instr. 4)		
				c	ode	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amoun or Numbe of Shares	1						
Restricted Stock Units	(1)	02/11/2021			A		9,375		(2)		(2)	Common Stock	9,375	\$0	9,37	5	D			

Stock Option (3) Common 02/11/2021 02/10/2031 56,250 \$30.66 56.250 D A 56.250 \$<mark>0</mark> (Right to Stock Buy) Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

2. The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date 3. The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.



02/16/2021

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.